SuperworthQ32 Bio QTTB
- Market cap
- $257.5M
- PE
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- one or more of the four quarters through 2026-06-30 missing
- EV/EBIT
- 7.3×
- Revenue, 12 months
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Net margin
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Free cash flow yield
- n/m
- not a meaningful number
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $1.9M+132% | $0 | $0 | $0 | $0 | $0 | n/a | n/a | n/a | n/a | n/a | n/a | |
| R&D | $7.5M−71% | $1.5M−94% | $9.8M+24% | $13.4M+67% | $14.3M+92% | $10.5M+597% | $7.1M−28% | $5.2M−62% | $3.6M−75% | $3.3M−69% | $3.2M−55% | $4.3M−18% |
| SG&A | $2.2M−72% | $7.9M−3% | $5M+108% | $4.5M+83% | $4.5M+104% | $4M−50% | $5.1M+2% | $4M−11% | $4M−10% | $4.5M+14% | $4.5M−12% | $4.9M+21% |
| −$7.8M−76% | −$12.1M−65% | −$14.8M+101% | −$17.9M+146% | −$18.8M+141% | −$14.5M+20% | −$12.2M−18% | −$9.2M−49% | −$7.6M−60% | $45.9M | −$7.7M−37% | −$9.1M−1% | |
| Pre-tax income | −$14M−56% | −$2.2M−94% | $1.2M | −$15.5M+167% | −$17.6M+26% | −$14.2M+557% | −$11M | −$9.5M−39% | −$7.4M−58% | $57.7M | n/a | n/a |
| −$65K | $0 | $0 | $0 | $0 | $21K | $0 | $0 | n/a | n/a | n/a | n/a | |
| Net income | −$14M−58% | −$27.1M−21% | $1M | −$17M+192% | −$17.6M+25% | −$14.2M−48% | −$11M | −$9.5M−44% | −$7.4M−58% | $57.7M | −$7.6M−31% | −$8.9M−6% |
| −$40.52+282% | $75.14 | −$6.33−68% | −$1.42−92% | −$1.46−96% | n/a | −$0.90−86% | −$0.78−45% | −$0.60−59% | n/a | −$0.54−40% | −$0.44−44% | |
| 346.3K−89% | 354.3K−89% | 2.3M+577% | 12M+3339% | 12.1M+3387% | n/a | 12.2M+423% | 12.2M+2% | 12.2M+1% | n/a | 14.1M+16% | 20.3M+67% |
EPS, diluted: 7 periods, Q4 FY17 to Q4 FY23: quarter's net income to common over its shares, to the cent.
Diluted shares: 6 periods, Q4 FY17 to Q4 FY22: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY23: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest Q32 Bio's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| QTTBQ32 Bio | $257.5M | n/m | n/a | n/m | n/m | n/m | |
| NATRNatures Sunshine Products | $213.8M | 12.0× | 20.6× | 0.4× | +7% | 3.7% | |
| ARVNArvinas | $477.3M | 45.6× | 52.3× | 1.5× | −15% | 2.9% | |
| PBYIPuma Biotechnology | $568.9M | 21.2× | 12.3× | 2.5× | −3% | 11.6% | |
| IRWDIronwood Pharmaceuticals | $571.7M | 4.5× | 14.9× | 1.5× | +26% | 33.4% | |
| ZVRAZevra Therapeutics | $582.6M | 10.5× | 12.3× | 4.3× | +119% | 42.8% | |
| CRMDCorMedix | $611.9M | 3.7× | 4.0× | 1.3× | +281% | 40.5% | |
| COLLCollegium Pharmaceutical | $747.5M | 18.5× | 19.1× | 0.9× | +14% | 5.9% | |
| ABUSArbutus Biopharma | $831M | 5.4× | 5.6× | 4.6× | n/m | 84.2% | |
| LFVNLifevantage | $73.4M | 14.7× | 19.6× | 0.4× | −20% | 2.8% | |
| SPROSpero Therapeutics | $64.6M | 10.1× | 9.5× | 1.4× | −3% | 15.7% | |
| Peer median | $570.3M | 11.3× | 13.6× | 1.4× | +7% | 13.6% |
More on Q32 Bio
Each number over time
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .